The azole antifungals are among the most pharmacokinetically interactive drugs in clinical medicine. Their interactions arise primarily from potent inhibition of cytochrome P450 (CYP) enzymes in the liver and intestinal wall, and from vulnerability to drugs that induce these same enzymes and reduce azole plasma concentrations to subtherapeutic levels. Understanding the mechanistic basis of these interactions is essential for managing them safely rather than simply memorizing a list of drug pairs.
CYP Enzyme Inhibition. The azoles inhibit CYP enzymes by coordinating their triazole nitrogen with the heme iron of the enzyme active site, blocking substrate access. This inhibition is rapid in onset, occurring within hours of the first dose, and largely reversible upon drug discontinuation. Inhibition raises plasma concentrations of co-administered drugs that depend on the same CYP isoforms for metabolism, potentially producing toxicity at doses that are otherwise safe. The magnitude of the interaction depends on the potency of the inhibition, the fraction of the victim drug metabolized by the inhibited enzyme, the therapeutic index of the victim drug, and the degree to which alternative metabolic pathways can compensate. Drugs with narrow therapeutic indices and high fractional metabolism through the inhibited CYP are the highest-risk interaction partners.1
CYP Isoform Selectivity Among Azoles. Different azoles inhibit overlapping but distinct profiles of CYP isoforms. Voriconazole inhibits CYP2C19 (cytochrome P450 2C19), CYP2C9 (cytochrome P450 2C9), and CYP3A4 (cytochrome P450 3A4) with roughly comparable potency, making it the broadest CYP inhibitor in the antifungal class. Posaconazole inhibits CYP3A4 selectively, with minimal effects on CYP2C19 or CYP2C9. Itraconazole inhibits CYP3A4 potently and is also a potent inhibitor of P-glycoprotein (P-gp), a drug efflux transporter that affects intestinal and hepatic drug disposition independently of CYP metabolism. Fluconazole inhibits CYP2C9 most potently and CYP3A4 to a lesser degree. Isavuconazole inhibits CYP3A4 moderately, with lower overall inhibitory potency than voriconazole or posaconazole. These differences in isoform selectivity produce meaningfully different interaction profiles for each agent and should guide agent selection in patients on complex drug regimens.12
CYP Enzyme Induction. While azoles are inhibitors of CYP enzymes, the azoles themselves are substrates of CYP enzymes and are therefore vulnerable to induction by drugs that upregulate CYP expression through activation of nuclear receptors, principally the pregnane X receptor (PXR). CYP inducers increase enzyme synthesis over days to weeks, progressively reducing concentrations of co-administered CYP substrates. The most potent inducers clinically relevant to antifungal therapy are rifampin (rifampicin), which induces CYP3A4, CYP2C19, CYP2C9, and P-gp simultaneously; rifabutin, which has a similar but less potent induction profile; antiepileptic drugs including phenytoin, carbamazepine, and phenobarbital; efavirenz and nevirapine (HIV antiretrovirals); and St. John's wort. For most azoles, co-administration with rifampin reduces plasma drug concentrations so severely that therapeutic levels cannot be maintained even with maximal dose escalation, making the combination contraindicated.2
Pharmacokinetic Interaction Types. Beyond CYP-mediated interactions, clinically significant antifungal interactions also arise through P-gp inhibition (itraconazole and, to a lesser extent, voriconazole and posaconazole inhibit P-gp, reducing intestinal efflux and increasing absorption of P-gp substrate drugs), gastric pH effects (posaconazole oral suspension requires acid for dissolution; proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) reduce posaconazole suspension absorption significantly), and breast cancer resistance protein (BCRP) inhibition by isavuconazole. The interaction between amphotericin B and other nephrotoxins is pharmacodynamic rather than pharmacokinetic: there is no change in drug concentrations but additive or synergistic nephrotoxicity occurs through concurrent renal tubular damage.12
Contraindicated with all azoles: rifampin, St. John's wort (inducers; reduce azole to subtherapeutic). Contraindicated with voriconazole and posaconazole: sirolimus (extreme exposure amplification; AUC increases of 500–1000%). Require dose reduction and TDM: tacrolimus, cyclosporine with any azole. Require monitoring: warfarin with fluconazole, voriconazole, or posaconazole (CYP2C9-mediated elevation of S-warfarin; INR check within 1–2 weeks). Rifabutin: partial inducer; dose adjustment of azole may permit use in some scenarios with TDM.
The clinical importance of an antifungal drug interaction is determined by whether the resulting change in drug exposure crosses the threshold for toxicity or subtherapeutic efficacy. This section reviews the major interaction categories by victim drug class, with emphasis on the interactions that cause the greatest harm and require the most systematic management.
Immunosuppressants: Calcineurin Inhibitors. Tacrolimus and cyclosporine are metabolized primarily by CYP3A4 (cytochrome P450 3A4) and transported by P-gp; both enzymes are inhibited by all of the azoles to varying degrees. Voriconazole and posaconazole produce the largest increases in calcineurin inhibitor concentrations, typically requiring tacrolimus dose reductions of 50 to 75% and cyclosporine reductions of 25 to 50% when an azole is initiated. Itraconazole elevates calcineurin inhibitor concentrations substantially through combined CYP3A4 and P-gp inhibition. Fluconazole has a more modest effect on tacrolimus, primarily through CYP3A4, and typically requires tacrolimus reductions of 25 to 50%. Isavuconazole elevates calcineurin inhibitor concentrations to a lesser degree than voriconazole or posaconazole, but dose reduction and close monitoring are still required. These reductions must be made proactively before the azole reaches steady state; reactive adjustment after the calcineurin inhibitor trough rises risks nephrotoxicity and neurotoxicity from supratherapeutic exposure.3
Immunosuppressants: Sirolimus and Everolimus. Sirolimus (rapamycin) is an mTOR (mammalian target of rapamycin) inhibitor used in renal transplantation and as anti-GVHD (graft-versus-host disease) therapy. It is metabolized almost exclusively by CYP3A4 and has a narrow therapeutic index, making it among the most interaction-sensitive drugs in clinical practice. Voriconazole and posaconazole increase sirolimus area under the concentration-time curve (AUC) by approximately 500 to 1000%, raising concentrations from therapeutic to profoundly toxic levels. This interaction is categorically contraindicated with both agents. Isavuconazole produces a substantial but smaller AUC increase and requires TDM (therapeutic drug monitoring) with dose reduction if the combination must be used. Everolimus has a similar but somewhat less extreme interaction profile and requires TDM whenever used with any azole.3
Anticoagulants and Antiplatelets. Warfarin is metabolized by CYP2C9 (S-warfarin, the more pharmacologically active enantiomer) and CYP3A4 (R-warfarin). Fluconazole and voriconazole are the most potent inhibitors of CYP2C9 among the azoles and significantly elevate the international normalized ratio (INR) by reducing S-warfarin clearance; INR monitoring within one to two weeks of starting or stopping an azole is mandatory, and warfarin dose reductions of 25 to 50% are commonly required. Posaconazole affects warfarin through CYP3A4 inhibition; the interaction is clinically significant but typically less severe than with fluconazole or voriconazole. Itraconazole also interacts with warfarin through CYP3A4. Direct oral anticoagulants (DOACs) including rivaroxaban and apixaban are CYP3A4 and P-gp substrates; azoles increase DOAC (direct oral anticoagulant) exposure, and this combination requires caution with dose modification in high-risk patients.4
Antiepileptic Drugs and CNS (Central Nervous System) Agents. Phenytoin and carbamazepine are both potent CYP (cytochrome P450) inducers and themselves CYP substrates, creating bidirectional interactions with azoles. Co-administration of phenytoin with voriconazole reduces voriconazole plasma concentrations by approximately 70% through CYP2C19 (cytochrome P450 2C19) and CYP2C9 induction, while voriconazole simultaneously elevates phenytoin concentrations by approximately 80% through CYP2C9 inhibition; the manufacturer requires doubling the voriconazole maintenance dose and close phenytoin monitoring if this combination is unavoidable. Carbamazepine co-administration with most azoles is contraindicated because it reduces azole concentrations to subtherapeutic levels. Midazolam and other CYP3A4-metabolized benzodiazepines and opioids (fentanyl, oxycodone, alfentanil) may reach dangerously elevated concentrations with azole co-administration, particularly in the perioperative and intensive care unit (ICU) setting.24
Efavirenz reduces voriconazole concentrations by approximately 77% and is listed as contraindicated with standard voriconazole dosing; the voriconazole maintenance dose must be doubled and efavirenz reduced if the combination is used. Ritonavir (used as a pharmacokinetic booster) simultaneously induces CYP2C19 (reducing voriconazole) and inhibits CYP3A4 (raising voriconazole): net effect unpredictable; avoid combination. Lopinavir/ritonavir elevates isavuconazole concentrations through CYP3A4 inhibition; TDM advisable. Fluconazole is generally the safest azole for use with antiretrovirals given its simpler interaction profile.
The interaction between azole antifungals and calcineurin inhibitors is the most consequential and most frequently encountered drug-drug interaction in transplant medicine. Failure to anticipate and proactively manage it is a leading cause of preventable calcineurin inhibitor toxicity in solid organ and hematopoietic stem cell transplant recipients. The following section provides the clinical framework for safe co-administration.
Mechanism and Magnitude by Azole. Tacrolimus is metabolized by CYP3A4 (cytochrome P450 3A4) in the intestinal wall and liver, and is a substrate of P-gp, which limits its oral bioavailability. Azole inhibition of intestinal CYP3A4 and P-gp increases tacrolimus absorption from the gut, and inhibition of hepatic CYP3A4 slows its elimination, producing combined first-pass and systemic pharmacokinetic enhancement. The magnitude of tacrolimus AUC (area under the concentration-time curve) increase follows the potency of the azole as a CYP3A4 inhibitor: voriconazole and posaconazole increase tacrolimus AUC by approximately 3- to 5-fold; itraconazole produces a comparable or greater increase; fluconazole typically produces a 2- to 3-fold AUC increase; isavuconazole produces approximately a 1.5- to 2-fold increase. Cyclosporine is metabolized by CYP3A4 but is less sensitive to P-gp inhibition, and the magnitude of interaction is generally somewhat smaller than for tacrolimus but clinically significant for all azoles.3
Dose Adjustment Protocol. When initiating an azole in a transplant recipient receiving a calcineurin inhibitor, the following sequence minimizes toxicity risk. First, the calcineurin inhibitor dose should be empirically reduced before the first azole dose is given, not after the trough rises. For tacrolimus with voriconazole or posaconazole, reduce the dose to approximately one-third of the current dose; with fluconazole, reduce to approximately half; with isavuconazole, reduce to approximately two-thirds. For cyclosporine with voriconazole or posaconazole, reduce by approximately 25 to 50%. Second, tacrolimus trough levels should be measured daily for the first five to seven days after azole initiation, as the full pharmacokinetic interaction develops over two to three days while the azole reaches steady state. Third, once the interaction has stabilized and target troughs are re-established, monitoring can revert to the routine post-transplant frequency. When the azole is discontinued, the reverse process occurs: calcineurin inhibitor concentrations fall as CYP3A4 inhibition reverses, requiring dose escalation to prevent rejection.35
Avoiding the Most Dangerous Combinations. Sirolimus and everolimus represent a special category because their extreme sensitivity to CYP3A4 inhibition makes safe co-administration with potent azoles effectively impossible at standard doses. For sirolimus specifically, voriconazole and posaconazole are categorically contraindicated. The clinical scenarios where this poses the greatest challenge are patients on sirolimus-based immunosuppression who develop invasive fungal infections requiring one of these azoles; in such cases, the preferred approach is to transition the patient from sirolimus to an alternative immunosuppressant before starting the azole, or to select a non-azole antifungal (an echinocandin or amphotericin B formulation) where the clinical situation allows. Isavuconazole with sirolimus requires close TDM (therapeutic drug monitoring) of both drugs; the sirolimus dose will typically need to be reduced to 20 to 40% of the standard dose, and tacrolimus can often be monitored daily to maintain safe troughs.3
Antifungal Selection Strategy in Transplant Patients. The interaction burden with calcineurin inhibitors is a major determinant of antifungal agent selection in transplant recipients. For patients with invasive candidiasis, an echinocandin is preferred not only because it is first-line for candidemia but because echinocandins have a substantially simpler interaction profile than azoles; among echinocandins, micafungin and anidulafungin have no significant calcineurin inhibitor interactions, making them pharmacokinetically the safest choices in transplant patients. When azoles are required (for aspergillosis prophylaxis or treatment), voriconazole and posaconazole are most commonly used despite the interaction burden, because their antifungal efficacy in these settings is well established; the interaction is managed rather than avoided. Itraconazole is used less frequently in transplant patients because of its erratic oral absorption and additional P-gp interaction burden.5
Step 1: Reduce tacrolimus dose BEFORE first azole dose (not reactively). Voriconazole or posaconazole: reduce to ~one-third current dose. Fluconazole: reduce to ~one-half current dose. Isavuconazole: reduce to ~two-thirds current dose. Step 2: Measure tacrolimus trough daily for Days 1–7 after azole initiation. Step 3: Adjust tacrolimus dose to re-establish target trough (center-specific, typically 5–15 ng/mL depending on transplant type and time post-transplant). Step 4: When azole is stopped, anticipate trough fall; increase tacrolimus dose prospectively and monitor daily for 5–7 days.
Therapeutic drug monitoring (TDM) is the practice of measuring drug concentrations in patient plasma to verify that dosing achieves target exposure ranges associated with efficacy while avoiding supratherapeutic concentrations linked to toxicity. TDM is not universally applicable to all drugs; its value is greatest when specific pharmacokinetic and pharmacodynamic conditions are met. For antifungal therapy, these conditions are clearly met for the triazole class and absent for the echinocandins.
Criteria for TDM Value. The four conditions under which TDM delivers clinical benefit are: (1) demonstrable exposure-response relationships for both efficacy and toxicity, so that measured concentrations predict outcomes; (2) a narrow therapeutic index, so that the range between minimum effective concentration and minimum toxic concentration is small; (3) high interpatient pharmacokinetic variability, so that the same dose produces substantially different concentrations among patients; and (4) non-linear or unpredictable pharmacokinetics, so that dose-to-concentration relationships cannot be reliably predicted from dose alone. Voriconazole satisfies all four criteria with particular force: published coefficient of variation for trough concentrations at standard doses exceeds 80%, driven by CYP2C19 (cytochrome P450 2C19) genotype, comedications, hepatic function, and severity of illness. The result is that two patients receiving identical doses may have trough concentrations differing by a factor of 10 or more.6
Exposure-Response Evidence for Voriconazole. Multiple clinical studies have established concentration-outcome relationships for voriconazole. Trough concentrations below 1.0 to 1.5 mg/L are consistently associated with increased rates of treatment failure in invasive aspergillosis. A large multicenter study by Dolton et al. found that troughs below 1.7 mg/L were associated with a significantly higher incidence of treatment failure compared to higher concentrations. Conversely, trough concentrations above 5.0 to 5.5 mg/L are associated with hepatotoxicity, neurotoxicity (hallucinations, encephalopathy, delirium), and visual adverse effects. The resulting therapeutic window of approximately 1.0 to 5.5 mg/L (with some authorities recommending an upper limit of 4.0 to 5.0 mg/L) forms the basis for clinical TDM practice. Achieving this window cannot be reliably done by dose adjustment alone without measured concentrations.67
Factors Driving Voriconazole Pharmacokinetic Variability. The CYP2C19 (cytochrome P450 2C19) genotype is the most important driver of voriconazole pharmacokinetic variability. Poor metabolizers (PM phenotype), who carry two loss-of-function alleles, have plasma concentrations four to five times higher than normal metabolizers (NM phenotype) at the same dose; ultrarapid metabolizers have concentrations that may be 50% lower than NM. Beyond genotype, hepatic function significantly affects voriconazole clearance: Child-Pugh class B or C liver disease elevates concentrations substantially. Comedication with CYP2C19 inhibitors (omeprazole, esomeprazole, and other proton pump inhibitors (PPIs)) further elevates concentrations. Inflammation and critical illness reduce CYP (cytochrome P450) enzyme activity and can acutely increase voriconazole exposure even without dose changes. The combination of these variables makes TDM at steady state (Day 5 to 7 of therapy) essential rather than optional in any patient receiving voriconazole for serious infection.7
Standard adult dose: 6 mg/kg IV loading ×2, then 4 mg/kg IV twice daily (or 200 mg oral twice daily). At these doses, published trough concentrations range from below 0.1 mg/L to above 10 mg/L in different patients. Without TDM, approximately 30–50% of patients will have subtherapeutic concentrations and another 20–30% will have supratherapeutic concentrations. TDM is the only reliable way to confirm that an individual patient is within the therapeutic window. Begin TDM at Day 5–7; repeat after any dose change, addition of interacting drug, or change in clinical status.
Practical implementation of antifungal TDM (therapeutic drug monitoring) requires knowledge of target concentration ranges, correct sampling methodology, the timing of steady state, and how to interpret concentrations in light of the clinical context. This section provides the operational framework for TDM across the agents for which monitoring is established, advisable, or situationally indicated.
Voriconazole TDM: Targets and Sampling. Voriconazole TDM is measured as a trough concentration (Cmin), defined as the plasma concentration immediately before the next scheduled dose. Steady state is achieved at approximately Day 5 to 7 of consistent twice-daily oral dosing or after 5 to 6 doses of intravenous therapy when a loading dose has been given. The target trough range is 1.0 to 5.5 mg/L; most authorities accept 1.0 to 5.0 mg/L as the working range in practice. A trough below 1.0 mg/L in a patient not responding to therapy warrants dose escalation; a trough below 0.5 mg/L in a non-responding patient on standard doses strongly suggests a pharmacokinetic problem (CYP2C19 (cytochrome P450 2C19) UM (ultrarapid metabolizer) phenotype, concurrent inducer, or non-adherence to fasting requirements) that dose increase alone may not resolve without identifying the cause. A trough above 5.5 mg/L in a patient with new neuropsychiatric symptoms or hepatotoxicity warrants dose reduction; in a patient tolerating treatment without adverse effects, the upper limit is more flexible, but sustained concentrations above 6 mg/L should prompt review. TDM should be repeated after any dose change, addition or removal of an interacting drug, change in hepatic function, or intercurrent illness that alters CYP (cytochrome P450) enzyme activity.67
Posaconazole TDM: Targets and Formulation Dependence. Posaconazole TDM is most critical when the oral suspension is used, given that formulation's highly variable and food-dependent absorption. The target trough for prophylaxis is above 0.7 mg/L; for treatment of established invasive fungal infection, the target is above 1.0 mg/L, with many experts recommending above 1.25 to 1.5 mg/L for treatment of mold infections. Trough sampling is performed at steady state, typically by Day 5 to 7 of therapy. For the delayed-release (DR) tablet formulation, TDM is less urgently required in straightforward cases because absorption is more consistent, but remains advisable in patients with gastrointestinal (GI) dysfunction, mucositis, documented drug interactions reducing posaconazole levels, or breakthrough invasive fungal infections despite apparent prophylaxis. Intravenous posaconazole bypasses absorption variability entirely; TDM is rarely needed for the IV formulation unless there is a specific concern about altered elimination.8
Itraconazole TDM. Itraconazole TDM is established practice for patients receiving oral therapy for invasive or serious fungal infections, given the drug's highly variable absorption. The target trough for treatment is above 0.5 mg/L for the capsule formulation and above 1.0 mg/L for the oral solution, with some authorities recommending above 1.0 to 2.0 mg/L for invasive mold disease. Itraconazole is extensively metabolized to hydroxyitraconazole, an active metabolite with comparable antifungal activity; some assays measure total itraconazole plus hydroxyitraconazole, and targets reported in older literature may reflect this combined measurement. Itraconazole capsule absorption is highly dependent on gastric acidity and high-fat food; the oral solution (in hydroxypropyl-beta-cyclodextrin vehicle) is better absorbed on an empty stomach. TDM helps identify the subset of patients with poor absorption who are at risk for treatment failure despite apparent compliance.89
Isavuconazole and Fluconazole TDM. Isavuconazole TDM has not been standardized into routine clinical practice at the time of current evidence. The drug's linear pharmacokinetics and high oral bioavailability independent of food make concentrations more predictable from dose than is the case for voriconazole, but variability still exists and interactions with CYP3A4 (cytochrome P450 3A4) inducers or inhibitors can produce clinically important concentration changes. TDM is situationally indicated for isavuconazole when the patient is receiving a CYP3A4 inducer, when clinical failure occurs despite apparent therapy, or when supratherapeutic concentrations are suspected (which may present as QTc shortening on ECG (electrocardiogram)). Fluconazole does not require routine TDM in most clinical scenarios because of its predictable, linear pharmacokinetics and wide therapeutic index in most indications; however, TDM may be appropriate in patients with extreme renal impairment (fluconazole is renally eliminated and dose adjustment is required below a creatinine clearance (CrCl) of 50 mL/min), in those receiving maximal doses for refractory candidiasis, or in neonates and severely ill patients where pharmacokinetics differ markedly from the healthy adult.910
Voriconazole: trough 1.0–5.5 mg/L; sample at Day 5–7; repeat after dose or status change. Posaconazole suspension: trough above 0.7 mg/L (prophylaxis), above 1.0–1.5 mg/L (treatment); sample Day 5–7. Posaconazole DR tablet: TDM advisable in high-risk patients. Itraconazole: trough above 0.5–1.0 mg/L (formulation-dependent); combined itraconazole + hydroxyitraconazole above 1.0 mg/L commonly used. Isavuconazole: no established routine target; TDM when inducers or failure present. Fluconazole: routine TDM not required; adjust dose for CrCl below 50 mL/min. Echinocandins: TDM not established for clinical practice.
Safe antifungal prescribing in patients with complex drug regimens requires a systematic approach applied at every step: before drug selection, at initiation, during therapy, and at discontinuation. This framework integrates the interaction and TDM (therapeutic drug monitoring) principles from the preceding sections into actionable clinical practice.
Pre-Prescription Interaction Screening. Before selecting an antifungal agent, the clinician should identify all current medications and classify each by its CYP (cytochrome P450) interaction risk profile. The following categories require specific attention. Any drug with a narrow therapeutic index metabolized by CYP3A4 (cytochrome P450 3A4), CYP2C9 (cytochrome P450 2C9), or CYP2C19 (cytochrome P450 2C19) is a potential victim of azole inhibition; dose reduction and monitoring planning must be in place before the azole is started. Any potent CYP3A4 inducer (rifampin, rifabutin, phenytoin, carbamazepine, efavirenz) will reduce azole concentrations, potentially to subtherapeutic levels; if these drugs cannot be discontinued, either azole dose escalation with TDM or substitution with an echinocandin should be considered. Sirolimus or everolimus in the current regimen is an absolute flag; changing immunosuppression or choosing a non-azole antifungal should be strongly considered before initiating a potent azole. Proton pump inhibitors and H2RAs reduce posaconazole suspension absorption significantly; switching to the DR (delayed-release) tablet or IV formulation, or choosing a different antifungal, should be considered if the oral suspension is the only available posaconazole form.15
Agent Selection Guided by Interaction Profile. When multiple antifungal agents have equivalent clinical efficacy for a given indication, the agent with the most manageable interaction profile for that specific patient should be selected. In patients on complex immunosuppressive regimens with sirolimus or multiple CYP3A4-sensitive drugs, an echinocandin is often preferred for Candida coverage, with voriconazole or isavuconazole reserved for mold coverage where echinocandins are insufficient. Among azoles required for mold disease in transplant patients, isavuconazole has a somewhat lower interaction burden than voriconazole or posaconazole, which may favor its selection when calcineurin inhibitor interactions are difficult to manage. For patients receiving rifampin-based anti-tuberculosis (TB) therapy who require antifungal coverage for candidiasis, an echinocandin (whose concentrations are not significantly affected by rifampin induction) is a more reliable choice than any azole.25
Monitoring During Therapy. Once an antifungal-drug interaction pair is initiated, the monitoring plan must be structured and documented. For calcineurin inhibitor pairs with azoles: daily trough levels for the first week, then standard transplant monitoring. For warfarin with any azole: INR (international normalized ratio) at one to two weeks and after any dose change. For voriconazole: trough at Day 5 to 7 and after any change in clinical status, interacting drug, or dose. For posaconazole suspension: trough at Day 5 to 7. For drugs with long half-lives (statins, some antiepileptics), full pharmacokinetic equilibration with the new interaction state may take longer than the conventional five-day steady-state estimate; monitoring should continue until stable. Systematic documentation of interaction pairs, planned adjustments, and target trough ranges in the medication record reduces errors when patients transition between providers or care settings.56
Antifungal Discontinuation. The end of antifungal therapy is as pharmacokinetically significant as the start, and drug interactions at discontinuation are a common source of preventable harm. When a CYP-inhibiting azole is stopped, all co-administered drug concentrations that were elevated by the inhibition will fall. For calcineurin inhibitors this means subtherapeutic troughs and risk of rejection; the calcineurin inhibitor dose must be increased (to the pre-azole baseline as a starting point) and trough levels measured daily for five to seven days as the inhibition resolves over two to five days. For anticoagulants, INR will fall after azole discontinuation as warfarin clearance normalizes; the anticoagulation team must be alerted. For drugs being held because of the interaction during azole therapy (such as a statin withheld to avoid myopathy), restart can be planned once the azole is stopped. Conversely, when a CYP inducer is stopped in a patient maintained on a higher azole dose (for example, voriconazole 400 mg twice daily to compensate for rifampin induction), the azole dose must be promptly reduced to standard dosing to prevent toxicity as induction reverses over one to two weeks.5
Azoles inhibit CYP enzymes (especially CYP3A4, CYP2C9, CYP2C19) and are themselves vulnerable to CYP inducers. The calcineurin inhibitor interaction is the most clinically consequential: proactively reduce tacrolimus before starting any azole; monitor daily for 7 days; reverse the process on discontinuation. Sirolimus with voriconazole or posaconazole: contraindicated. Warfarin with fluconazole or voriconazole: monitor INR within 1–2 weeks. Rifampin with any azole: usually contraindicated (reduces azole to subtherapeutic). Voriconazole TDM is mandatory: target trough 1.0–5.5 mg/L; sample at Day 5–7. Posaconazole TDM is advisable with suspension: target above 0.7 mg/L (prophylaxis), above 1.0–1.5 mg/L (treatment). Echinocandins: minimal interaction burden; no routine TDM.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38(2):111-180.
doi:10.2165/00003088-200038020-00002Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother. 2005;6(13):2231-2243.
doi:10.1517/14656566.6.13.2231Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43(Suppl 1):S28-S39.
doi:10.1086/504492Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26(12):1730-1744.
doi:10.1592/phco.26.12.1730Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30(8):842-854.
doi:10.1592/phco.30.8.842Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(9):4793-4799.
doi:10.1128/AAC.00626-12Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child. 2008;93(7):578-581.
doi:10.1136/adc.2007.118182Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24-34.
doi:10.1128/AAC.00705-08Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441-1458.
doi:10.1086/598327Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
doi:10.1093/cid/civ933